Immunotherapy trials reveal 'encouraging' results for melanoma treatment
6/03/2014
Two new studies reveal how the drugs nivolumab, ipilimumab and pembrolizumab improved overall survival for patients with advanced melanoma, showing promise for new treatments.
Patients with terminal illnesses benefit from stopping statins
6/03/2014
Cholesterol-lowering statins are widely used, but new research suggests patients in late stages of terminal illnesses may extend their lives by discontinuing use of the drug.
VELCADE Phase 3 study results presented for patients with mantle cell lymphoma
6/03/2014
Millennium: The Takeda Oncology Company has announced results from the primary analysis of an international, randomized Phase 3 study that showed treatment with a VELCADE® (bortezomib)-based...
Reduced kidney function associated with higher risk of renal and urothelial cancer
6/03/2014
A key measure of reduced kidney function and chronic kidney disease - reduced glomerular filtration rate - is an independent risk factor for renal and urothelial cancer, according to a study...
New treatment option for young women with hormone-sensitive breast cancer
6/03/2014
The aromatase inhibitor exemestane is more effective than tamoxifen in preventing breast cancer recurrence in young women who also receive ovarian function suppression as adjuvant (post-surgery)...
Study finds risk of recurrence low in smallest HER2+ breast cancer tumors
6/03/2014
Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a...
Risk of secondary cancers increased following radiation for prostate cancer
6/03/2014
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan...
Targeting cancer stem cells: results in phase I trial of OMP-54F28
6/03/2014
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an...
Support of ibrutinib strengthened as second-line therapy for CLL by phase 3 study
6/03/2014
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a...
Volatile organic compounds in exhaled breath show presence and stage of lung cancer
6/03/2014
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled...